HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Observational study of adjuvant therapy with capecitabine in colon cancer.

AbstractOBJECTIVE:
This observational study was conducted to document the safety of capecitabine-based adjuvant therapy in patients with resected colon cancer under routine clinical conditions.
RESEARCH AND DESIGN METHODS:
ML20431 was a prospective, multicenter, non-interventional, observational study. It was designed to answer five research questions relating to safety, dosage and administration, and discontinuation from capecitabine-based adjuvant therapy. Patients were required to have R0 resected stage III colon cancer and have started treatment with capecitabine-based adjuvant therapy based on a decision by the investigator. Patients were followed over an observation period of ≤6 months after initiation of therapy. Investigators were required to complete the study case report form at study entry, each treatment cycle, and at the final examination.
MAIN OUTCOME MEASURES:
A total of 1485 patients were included in the study, and 1481 patients were treated with capecitabine and formed the analysis population. Most patients had colon cancer (78.3%), followed by rectal cancer (16.4%). Most patients had stage III disease (69.3%); the remaining patients had stage II disease (30.7%). The most common all-grade adverse reactions were hand-foot syndrome (46.9%), diarrhea (34.4%), and hemoglobin decreases (31.5%). Grade 3/4 adverse reactions were infrequent (<4%). Serious adverse events were reported in 96 patients (6.5%). Six or more cycles of treatment were completed by 77.9% of patients. Approximately two-thirds of patients (67.3%) received capecitabine monotherapy and the remainder (32.7%) received capecitabine in combination with ≥1 drugs, most commonly oxaliplatin (460 cases). Discontinuation of capecitabine was documented in 344 patients (23.2%).
STUDY LIMITATIONS:
no efficacy data were collected; the questionnaires for patients' expectations and satisfaction were not formally validated; and a few patients (<1.5%) had some retrospective data.
CONCLUSIONS:
The safety profile of capecitabine-based adjuvant therapy in a broad patient population with colon cancer is similar to that previously documented in phase III clinical trials.
AuthorsClaus-Christoph Steffens, Barbara Tschechne, Christof Schardt, Georg Jacobs, Annette-Rosel Valdix, Peter Schmidt, Richard Hansen, Hendrik Kröning, Tim Wohlfarth, Dorothee Guggenberger
JournalCurrent medical research and opinion (Curr Med Res Opin) Vol. 31 Issue 4 Pg. 731-41 (Apr 2015) ISSN: 1473-4877 [Electronic] England
PMID25651480 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Organoplatinum Compounds
  • Oxaliplatin
  • Deoxycytidine
  • Capecitabine
  • Fluorouracil
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Capecitabine
  • Chemotherapy, Adjuvant (methods)
  • Colonic Neoplasms (drug therapy)
  • Combined Modality Therapy
  • Deoxycytidine (analogs & derivatives, therapeutic use)
  • Female
  • Fluorouracil (analogs & derivatives, therapeutic use)
  • Humans
  • Male
  • Organoplatinum Compounds (administration & dosage)
  • Oxaliplatin
  • Prospective Studies
  • Rectal Neoplasms (drug therapy)
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: